175 related articles for article (PubMed ID: 17804673)
1. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.
Perkovic V; Ninomiya T; Arima H; Gallagher M; Jardine M; Cass A; Neal B; Macmahon S; Chalmers J
J Am Soc Nephrol; 2007 Oct; 18(10):2766-72. PubMed ID: 17804673
[TBL] [Abstract][Full Text] [Related]
2. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease.
Campbell DJ; Woodward M; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Neal BC; Patel A; MacMahon SW
J Hypertens; 2007 Mar; 25(3):699-705. PubMed ID: 17278987
[TBL] [Abstract][Full Text] [Related]
3. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy.
Dufouil C; Chalmers J; Coskun O; Besançon V; Bousser MG; Guillon P; MacMahon S; Mazoyer B; Neal B; Woodward M; Tzourio-Mazoyer N; Tzourio C;
Circulation; 2005 Sep; 112(11):1644-50. PubMed ID: 16145004
[TBL] [Abstract][Full Text] [Related]
4. Making PROGRESS in stable patients post stroke or transient ischaemic attack: implications for general practice.
Jackson G
Int J Clin Pract; 2003 Jun; 57(5):385-7. PubMed ID: 12846342
[TBL] [Abstract][Full Text] [Related]
5. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; Harrap S; Hamet P; Poulter N; Lip GY; Patel A;
Eur Heart J; 2009 May; 30(9):1128-35. PubMed ID: 19282274
[TBL] [Abstract][Full Text] [Related]
6. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
Tavakoli M; Pumford N; Woodward M; Doney A; Chalmers J; MacMahon S; Macwalter R
Eur J Health Econ; 2009 Feb; 10(1):111-9. PubMed ID: 18446392
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease.
Campbell DJ; Neal BC; Chalmers JP; Colman SA; Jenkins AJ; Kemp BE; Patel A; Macmahon SW; Woodward M
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):413-8. PubMed ID: 17568241
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
Chalmers J; Joshi R; Kengne AP; Ninomiya T; Bi Y; Bompoint S; Billot L; Patel A;
J Hypertens Suppl; 2008 Sep; 26(3):S21-7. PubMed ID: 19363849
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure reduction and risk of dementia in patients with stroke: rationale of the dementia assessment in PROGRESS (Perindopril Protection Against Recurrent Stroke Study). PROGRESS Management Committee.
Tzourio C; Anderson C;
J Hypertens Suppl; 2000 May; 18(1):S21-4. PubMed ID: 10939786
[TBL] [Abstract][Full Text] [Related]
11. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
12. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial.
Chapman N; Huxley R; Anderson C; Bousser MG; Chalmers J; Colman S; Davis S; Donnan G; MacMahon S; Neal B; Warlow C; Woodward M;
Stroke; 2004 Jan; 35(1):116-21. PubMed ID: 14671247
[TBL] [Abstract][Full Text] [Related]
13. Evidence for benefits of perindopril in hypertension and its complications.
Laurent S
Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
[TBL] [Abstract][Full Text] [Related]
14. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts JJ; Ferrari R; Simoons ML
Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
17. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
[TBL] [Abstract][Full Text] [Related]
18. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
19. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial.
Arima H; Chalmers J; Woodward M; Anderson C; Rodgers A; Davis S; Macmahon S; Neal B;
J Hypertens; 2006 Jun; 24(6):1201-8. PubMed ID: 16685221
[TBL] [Abstract][Full Text] [Related]
20. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
